Presentation is loading. Please wait.

Presentation is loading. Please wait.

K OREAN ADNI … WHERE ARE WE NOW Seol-Heui Han, MD, PhD. On behalf of Preparatory Committee for K-ADNI Seol-Heui Han, MD, PhD. On behalf of Preparatory.

Similar presentations


Presentation on theme: "K OREAN ADNI … WHERE ARE WE NOW Seol-Heui Han, MD, PhD. On behalf of Preparatory Committee for K-ADNI Seol-Heui Han, MD, PhD. On behalf of Preparatory."— Presentation transcript:

1 K OREAN ADNI … WHERE ARE WE NOW Seol-Heui Han, MD, PhD. On behalf of Preparatory Committee for K-ADNI Seol-Heui Han, MD, PhD. On behalf of Preparatory Committee for K-ADNI

2 9yr Project 700,000 US dollars /yr Funded by the Ministry of Health, Welfare, and Family Affairs Clinical Research Center for Dementia of South Korea (CREDOS)

3 Primary focus of CREDOS svMCI aMCI AD SVaD Time Cognition Healthy, Healthy, SMI

4 Items for history Cognition ADL Behaviors Differential diagnoses Scales or questionnaires Korean Dementia Screening Questionnaire (K-DSQ) Barthel- index Instrumental ADL (Seoul IADL) NPI MMSE CDR GDS Hachinski ischemic scale Geriatric depression scale Items for history Cognition ADL Behaviors Differential diagnoses Scales or questionnaires Korean Dementia Screening Questionnaire (K-DSQ) Barthel- index Instrumental ADL (Seoul IADL) NPI MMSE CDR GDS Hachinski ischemic scale Geriatric depression scale CREDOS CREDOS protocols MRI Lab Vitamin B12 Folate VDRL TSH/free T4 Axial T2, T1, FLAIR, (GRE) Coronal T1 Neuropsychological tests

5 CREDOS D-Matrix WMH on MRI minimalmoderatesevere COGNITIONCOGNITION No cognitive impairmentI-1 I-2I-3 Mild cognitive impairmentII-1 II-2II-3 Mild to moderate dementiaIII-1 III-2III-3 Severe dementiaIV-1 IV-2IV-3 Healthy, SMI aMCI, AD svMCI, SIVD

6

7 DESIGNING K-ADNI

8 K-ADNI: Organization Tree K-ADNI PI: SH Han Clinical Core Biological Core Imaging Core Biostatistics Core Assistant administrator: SY Kim, DW Yang CREDOS PI:DL Na Advisory board ADNI: M. Weiner Stroke risk ADAS-Cog, CDR ADL,NPI, FBI Neurologic scale CSF tau, amyloid Apo E, GWAS Lipid, homocysteine, TFT MRI-VBM, DTI, fMRI FDG-PET, PIB-PET

9 Main aim: Effects of SVD on Progression of AD Time Cognition

10 Plan: 500 cases No cognitive impairment10000 Mild cognitive impairment10050 Mild to moderate dementia10050 Severe dementia000 WMH on MRI mildmoderatesevere Cognition

11 Recruitment N=500 Follow up K-ADNI Longitudinal 5yr Longitudinal study Neuropsychological Tests SNSB, ADL,CGA-NPI, FBI Biomarker Blood: Apo E polymorphism, Genome-wide study CSF Imaging studies MRI PET: FDG-PET, PIB-PET NPT Biomarker Imaging NPT Biomarker Imaging NPT Biomarker Imaging NPT Biomarker Imaging NPT Biomarker Imaging NPT Biomarker Imaging

12 Ready to go  Funding sources ($1.5 M/yr for 5 years)  Government  Private donations  Industry support


Download ppt "K OREAN ADNI … WHERE ARE WE NOW Seol-Heui Han, MD, PhD. On behalf of Preparatory Committee for K-ADNI Seol-Heui Han, MD, PhD. On behalf of Preparatory."

Similar presentations


Ads by Google